28 juli 2011: ik ben kanker-actueel aan het herzien en heb onder dit artikel een recenter studieabstract toegevoegd over dit vaccinatie programma bij maagkanker. Al is dat ook al weer uit 2007. Wel beetje vreemd dat er niet recentere publicaties zijn over dit middel.

25 mei 2006: Bron: Cancer 2006;106:1908-1916.

Een vaccinatie programma met een mix van "amino-terminal sequence of gastrin 17 en diftheria toxoid" onder codenaam G17DT geeft bemoedigende resultaten te zien bij patiënten met gevorderde maagkanker en slokdarmkanker.

Om het effect te meten van G17DT, zetten de onderzoekers een open label studie op van onbehandelde patiënten met maagkanker die in de weken 1, 5, 9 en 25 intramusculair werden gevaccineerd. Zij kregen daarnaast cisplatin en 5-fluorouracil elke 28 dagen. In total, 79 patients were evaluated for overall response and 94 were evaluated for immune response. The overall response rate was 30% and 69% were deemed to be successful immune responders. The median time to progression was 5.4 months. De tijd tot progressie van de ziekte was significant hoger bij de patiënten die goed op de vaccinatie regeerden in vergelijking met niet-responders. Dit gold ook voor de overall overlevingstijd -- 10.3 maanden versus 3.8 maanden.

Successvolle vaccinatie was een significante onafhankelijke overall overlevings prognosefactor en was onafhankelijk van andere klinische factoren. G17DT gaf geen negatief effect op de veiligheid van de behandeling.

Immunogen Improves Survival in Gastric Cancer By David Douglas NEW YORK (Reuters Health) May 24 - Successful vaccination with the therapeutic immunogen G17DT appears beneficial in patients with advanced gastric or gastroesophageal cancer, researchers report in the May 1st issue of Cancer. As lead investigator Dr. Jaffer A. Ajani told Reuters Health, "I believe that the results are intriguing. Patients who were successfully immunized seemed to have a higher response rate and longer survival." Dr. Ajani of the University of Texas MD Anderson Cancer Center, Houston and colleagues explain that G17DT is a conjugate of the amino-terminal sequence of gastrin 17 and diphtheria toxoid. The agent elicits a specific and high-affinity antigastrin antibody response that is antiproliferative and antimetastatic. To investigate the effect of G17DT, the researchers conducted an open-label study of untreated patients with gastric adenocarcinoma who were vaccinated intramuscularly on weeks 1, 5, 9 and 25. They were also given cisplatin and 5-fluorouracil every 28 days. In total, 79 patients were evaluated for overall response and 94 were evaluated for immune response. The overall response rate was 30% and 69% were deemed to be successful immune responders. The median time to progression was 5.4 months. The time to progression was significantly longer in immune responders than non-responders. This was also true of median survival -- 10.3 months versus 3.8 months. Successful vaccination was a significant independent overall survival prognosticator and was independent of other clinical factors. G17DT did not have an adverse effect on safety. Thus, added Dr. Ajani, the "immunization effort needs to improve -- with a more aggressive vaccination strategy." Overall, the researchers conclude, "A phase III investigation of G17DT is warranted to delineate its true contribution to patient survival." Cancer 2006;106:1908-1916.

G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy

G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy

 

March 2007, Vol. 7, No. 3 , Pages 397-404 (doi:10.1517/14712598.7.3.397)
1
1University of Nottingham, Division of Preclinical Oncology, D Floor, West Block, Queen’s Medical Centre, University Hospital, Nottingham, NG7 2UH, UK. sue.watson@nottingham.ac.uk
† Author for correspondence

 



G17DT (Gastrimmune) is an antigastrin-17 immunogen, raising antibodies that blockade gastrin-stimulated tumor growth. It has completed Phase III trials in patients with pancreatic cancer, and Phase III trials in gastric cancer are planned. Preclinical studies have confirmed that the G17DT-induced antibodies both reduce gastrin-17-stimulated gastric acid secretion and inhibit gastrin from interacting with the cholecystokinin-2 receptor. The efficacy of both passive and active immunization with G17DT has been established in a number of tumor systems, with additive effects demonstrated in combination chemotherapy in pancreatic, colon and gastric tumor models. Phase I/II studies in advanced gastrointestinal malignancies have shown no systemic or autoimmune reactions to active immunization with G17DT. The use of an optimized dose and dosing schedule has yielded a high proportion of antibody responders (70%), with minimal side effects and antibody titers measurable within 2 – 4 weeks. Phase II trials of G17DT in combination with chemotherapy have also been conducted in gastric and colorectal cancer. A Phase III, multicenter, double-blind, randomized, controlled trial of G17DT versus placebo in patients with advanced pancreatic cancer confirmed improved survival of patients in the G17DT group through an intention-to-treat analysis. The results of a randomized, double-blind, multinational, multicenter study of G17DT in combination with gemcitabine versus placebo and gemcitabine in patients with advanced pancreatic cancer failed to show improved overall survival except on subset analysis of patients with high antibody titers. Therefore, G17DT represents an emerging new modality for gastrointestinal malignancy.




Read More: http://informahealthcare.com/doi/abs/10.1517/14712598.7.3.397%20
G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy

 

March 2007, Vol. 7, No. 3 , Pages 397-404 (doi:10.1517/14712598.7.3.397)
1
1University of Nottingham, Division of Preclinical Oncology, D Floor, West Block, Queen’s Medical Centre, University Hospital, Nottingham, NG7 2UH, UK. sue.watson@nottingham.ac.uk
† Author for correspondence

 



G17DT (Gastrimmune) is an antigastrin-17 immunogen, raising antibodies that blockade gastrin-stimulated tumor growth. It has completed Phase III trials in patients with pancreatic cancer, and Phase III trials in gastric cancer are planned. Preclinical studies have confirmed that the G17DT-induced antibodies both reduce gastrin-17-stimulated gastric acid secretion and inhibit gastrin from interacting with the cholecystokinin-2 receptor. The efficacy of both passive and active immunization with G17DT has been established in a number of tumor systems, with additive effects demonstrated in combination chemotherapy in pancreatic, colon and gastric tumor models. Phase I/II studies in advanced gastrointestinal malignancies have shown no systemic or autoimmune reactions to active immunization with G17DT. The use of an optimized dose and dosing schedule has yielded a high proportion of antibody responders (70%), with minimal side effects and antibody titers measurable within 2 – 4 weeks. Phase II trials of G17DT in combination with chemotherapy have also been conducted in gastric and colorectal cancer. A Phase III, multicenter, double-blind, randomized, controlled trial of G17DT versus placebo in patients with advanced pancreatic cancer confirmed improved survival of patients in the G17DT group through an intention-to-treat analysis. The results of a randomized, double-blind, multinational, multicenter study of G17DT in combination with gemcitabine versus placebo and gemcitabine in patients with advanced pancreatic cancer failed to show improved overall survival except on subset analysis of patients with high antibody titers. Therefore, G17DT represents an emerging new modality for gastrointestinal malignancy.




Read More: http://informahealthcare.com/doi/abs/10.1517/14712598.7.3.397%20
G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy

 

March 2007, Vol. 7, No. 3 , Pages 397-404 (doi:10.1517/14712598.7.3.397)
1
1University of Nottingham, Division of Preclinical Oncology, D Floor, West Block, Queen’s Medical Centre, University Hospital, Nottingham, NG7 2UH, UK. sue.watson@nottingham.ac.uk
† Author for correspondence

 



G17DT (Gastrimmune) is an antigastrin-17 immunogen, raising antibodies that blockade gastrin-stimulated tumor growth. It has completed Phase III trials in patients with pancreatic cancer, and Phase III trials in gastric cancer are planned. Preclinical studies have confirmed that the G17DT-induced antibodies both reduce gastrin-17-stimulated gastric acid secretion and inhibit gastrin from interacting with the cholecystokinin-2 receptor. The efficacy of both passive and active immunization with G17DT has been established in a number of tumor systems, with additive effects demonstrated in combination chemotherapy in pancreatic, colon and gastric tumor models. Phase I/II studies in advanced gastrointestinal malignancies have shown no systemic or autoimmune reactions to active immunization with G17DT. The use of an optimized dose and dosing schedule has yielded a high proportion of antibody responders (70%), with minimal side effects and antibody titers measurable within 2 – 4 weeks. Phase II trials of G17DT in combination with chemotherapy have also been conducted in gastric and colorectal cancer. A Phase III, multicenter, double-blind, randomized, controlled trial of G17DT versus placebo in patients with advanced pancreatic cancer confirmed improved survival of patients in the G17DT group through an intention-to-treat analysis. The results of a randomized, double-blind, multinational, multicenter study of G17DT in combination with gemcitabine versus placebo and gemcitabine in patients with advanced pancreatic cancer failed to show improved overall survival except on subset analysis of patients with high antibody titers. Therefore, G17DT represents an emerging new modality for gastrointestinal malignancy.




Read More: http://informahealthcare.com/doi/abs/10.1517/14712598.7.3.397%20
Expert Opin Biol Ther. 2007 Mar;7(3):397-404.

G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy.

Source

University of Nottingham, Division of Preclinical Oncology, D Floor, West Block, Queen's Medical Centre, University Hospital, Nottingham, NG7 2UH, UK.

Abstract

G17DT (Gastrimmune) is an antigastrin-17 immunogen, raising antibodies that blockade gastrin-stimulated tumor growth. It has completed Phase III trials in patients with pancreatic cancer, and Phase III trials in gastric cancer are planned. Preclinical studies have confirmed that the G17DT-induced antibodies both reduce gastrin-17-stimulated gastric acid secretion and inhibit gastrin from interacting with the cholecystokinin-2 receptor. The efficacy of both passive and active immunization with G17DT has been established in a number of tumor systems, with additive effects demonstrated in combination chemotherapy in pancreatic, colon and gastric tumor models. Phase I/II studies in advanced gastrointestinal malignancies have shown no systemic or autoimmune reactions to active immunization with G17DT. The use of an optimized dose and dosing schedule has yielded a high proportion of antibody responders (70%), with minimal side effects and antibody titers measurable within 2 - 4 weeks. Phase II trials of G17DT in combination with chemotherapy have also been conducted in gastric and colorectal cancer. A Phase III, multicenter, double-blind, randomized, controlled trial of G17DT versus placebo in patients with advanced pancreatic cancer confirmed improved survival of patients in the G17DT group through an intention-to-treat analysis. The results of a randomized, double-blind, multinational, multicenter study of G17DT in combination with gemcitabine versus placebo and gemcitabine in patients with advanced pancreatic cancer failed to show improved overall survival except on subset analysis of patients with high antibody titers. Therefore, G17DT represents an emerging new modality for gastrointestinal malignancy.

PMID:
17309331
[PubMed - indexed for MEDLINE]

Plaats een reactie ...

Reageer op "Vaccinatieprogramma bij maagkanker en slokdarmkanker onder codenaam G17DT geeft hoopvolle resultaten in studiegroep van totaal 173 eerder onbehandelde maagkanker- en slokdarmkankerpatiënten. Mediane levensduur ging van 3,8 naar 10,3 maanden."


Gerelateerde artikelen
 

Gerelateerde artikelen

Aanbevolen abstracten voor >> Maagkanker: Overzicht van >> Bestraling na operatie aanvullend >> Chemotherapie met oraal capecitabine >> Cimetidine (productnaam Tagamet-800), >> Diagnose: Ademtest kan maagkanker >> Helicobacter Pylori bacterie: >> Herceptin aanvullend op chemo >> Hypec: Combinatiebehandeling >> Immuuntherapie bij maagkanker: >>